Articles from Parnell

Parnell today announced the launch of Sevoflurane Inhalation Anesthetic, expanding its anesthesia portfolio to better support veterinary teams across the full procedural workflow. Indicated for the induction and maintenance of general anesthesia in dogs, the new offering provides clinics with a reliable, cost-effective inhalant anesthetic option from a company veterinary teams already rely on.

Parnell today announced the acquisition of Noble Pharma LLC, a U.S.-based pharmaceutical manufacturer, according to the Securities Purchase Agreement dated November 26, 2025.

Parnell Technologies Pty. Ltd. announced the U.S. launch of nixiFLOR® (florfenicol and flunixin meglumine) injectable solution, recently approved by the U.S. Food and Drug Administration for the treatment of bovine respiratory disease (BRD) and control of BRD-associated pyrexia (fever) in beef and non-lactating dairy cattle.

Parnell today announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials.

Parnell is proud to announce the launch of its new Isoflurane Inhalation Anesthetic, a nonflammable and nonexplosive solution designed for the induction and maintenance of general anesthesia in horses and dogs.

SYDNEY, AUSTRALIA / ACCESSWIRE / July 14, 2021 / Parnell Pharmaceuticals Holdings Ltd (OTC PINK:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Thursday, 5th August 2021 at 8:30 a.m. (Australian Eastern Standard Time) NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM Notice